🎯 Key Takeaways for quick navigation: 00:34 💡 The presentation is about heart failure in type 2 diabetes, discussing its causes, how to diagnose it, and its management, particularly with respect to sglt2. 01:48 📌 Heart failure in diabetes patients is worse than heart failure in patients without diabetes. Good glycemic control doesn't necessarily reduce the risk of worsening of heart failure in a diabetic patient. 05:28 🩺 An important tool for diagnosing heart failure in diabetes patients is the biomarker npro BNP. If the value is more than 125 microgram per ml, it's strongly suggestive of potential heart failure. 09:28 ⚠️ Diabetic cardiomyopathy, which describes any diabetes-associated structural or functional disorders of the myocardium not directly attributable to factors like CAD or hypertension, is more common than generally thought and often overlooked. 14:43 🚫 There are certain medications that should be avoided in patients with diabetes and heart failure, such as thiazolidinediones and DPP4 inhibitors with potential heart failure precipitation, like saxagliptin. 19:34 🌟 SGLT2 inhibitors are now a cornerstone of heart failure management in diabetes patients. This is backed by both data and guidelines, and it makes sense from a pathophysiological perspective as well. 20:30 💡 The presenter emphasizes the remarkable and statistically significant effectiveness of SGLT2 inhibitors in heart failure management. 20:58 🩺 In terms of heart failure management, guidelines recommend drugs such as ACE inhibitors, ARB, MRA and SGLT2 inhibitors among others. 21:27 🌿 SGLT2 inhibitors improve endothelial dysfunction and reduce insulin resistance which are common in diabetes and heart failure cases. 22:09 👍 SGLT2 inhibitors also enhance the utilization of glucose and increase ketone bodies which in turn improves the efficiency of cardiac muscles and the quality of life of patients. 22:50 📍 SGLT2 inhibitors also decrease ectopic and pericardial fat, leading to improved cardiac output. Made with HARPA AI
Thank you very much
🎯 Key Takeaways for quick navigation:
00:34 💡 The presentation is about heart failure in type 2 diabetes, discussing its causes, how to diagnose it, and its management, particularly with respect to sglt2.
01:48 📌 Heart failure in diabetes patients is worse than heart failure in patients without diabetes. Good glycemic control doesn't necessarily reduce the risk of worsening of heart failure in a diabetic patient.
05:28 🩺 An important tool for diagnosing heart failure in diabetes patients is the biomarker npro BNP. If the value is more than 125 microgram per ml, it's strongly suggestive of potential heart failure.
09:28 ⚠️ Diabetic cardiomyopathy, which describes any diabetes-associated structural or functional disorders of the myocardium not directly attributable to factors like CAD or hypertension, is more common than generally thought and often overlooked.
14:43 🚫 There are certain medications that should be avoided in patients with diabetes and heart failure, such as thiazolidinediones and DPP4 inhibitors with potential heart failure precipitation, like saxagliptin.
19:34 🌟 SGLT2 inhibitors are now a cornerstone of heart failure management in diabetes patients. This is backed by both data and guidelines, and it makes sense from a pathophysiological perspective as well.
20:30 💡 The presenter emphasizes the remarkable and statistically significant effectiveness of SGLT2 inhibitors in heart failure management.
20:58 🩺 In terms of heart failure management, guidelines recommend drugs such as ACE inhibitors, ARB, MRA and SGLT2 inhibitors among others.
21:27 🌿 SGLT2 inhibitors improve endothelial dysfunction and reduce insulin resistance which are common in diabetes and heart failure cases.
22:09 👍 SGLT2 inhibitors also enhance the utilization of glucose and increase ketone bodies which in turn improves the efficiency of cardiac muscles and the quality of life of patients.
22:50 📍 SGLT2 inhibitors also decrease ectopic and pericardial fat, leading to improved cardiac output.
Made with HARPA AI
Can we add low dose aspirin??
For primary prevention - little benefit